Literature DB >> 20158293

A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.

Kelly E Dunn1, Stacey C Sigmon, Edward F Reimann, Gary J Badger, Sarah H Heil, Stephen T Higgins.   

Abstract

Prevalence of cigarette smoking among opioid-maintained patients is more than threefold that of the general population and associated with increased morbidity and mortality. Relatively few studies have evaluated smoking interventions in this population. The purpose of the present study was to examine the efficacy of contingency management for promoting initial smoking abstinence. Forty methadone- or buprenorphine-maintained cigarette smokers were randomly assigned to a contingent (n = 20) or noncontingent (n = 20) experimental group and visited the clinic for 14 consecutive days. Contingent participants received vouchers based on breath carbon monoxide levels during Study Days 1 to 5 and urinary cotinine levels during Days 6 to 14. Voucher earnings began at $9.00 and increased by $1.50 with each subsequent negative sample for maximum possible of $362.50. Noncontingent participants earned vouchers independent of smoking status. Although not a primary focus, participants who were interested and medically eligible could also receive bupropion (Zyban). Contingent participants achieved significantly more initial smoking abstinence, as evidenced by a greater percentage of smoking-negative samples (55% vs. 17%) and longer duration of continuous abstinence (7.7 vs. 2.4 days) during the 2 week quit attempt than noncontingent participants, respectively. Bupropion did not significantly influence abstinence outcomes. Results from this randomized clinical trial support the efficacy of contingency management interventions in promoting initial smoking abstinence in this challenging population. (PsycINFO Database Record (c) 2010 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20158293      PMCID: PMC3605744          DOI: 10.1037/a0018649

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  70 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Smoking cessation among self-quitters.

Authors:  J R Hughes; S B Gulliver; J W Fenwick; W A Valliere; K Cruser; S Pepper; P Shea; L J Solomon; B S Flynn
Journal:  Health Psychol       Date:  1992       Impact factor: 4.267

3.  An experimental test of the influence of prior cigarette smoking abstinence on future abstinence.

Authors:  Sarah H Heil; Sheila M Alessi; Jennifer Plebani Lussier; Gary J Badger; Stephen T Higgins
Journal:  Nicotine Tob Res       Date:  2004-06       Impact factor: 4.244

4.  Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients.

Authors:  Kimber P Richter; Robert M McCool; Delwyn Catley; Matthew Hall; Jasjit S Ahluwalia
Journal:  J Addict Dis       Date:  2005

5.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  Changes in the relative reinforcing effects of cigarette smoking as a function of initial abstinence.

Authors:  Jin H Yoon; Stephen T Higgins; Matthew P Bradstreet; Gary J Badger; Colleen S Thomas
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

7.  Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women.

Authors:  Sarah H Heil; Stephen T Higgins; Ira M Bernstein; Laura J Solomon; Randall E Rogers; Colleen S Thomas; Gary J Badger; Mary Ellen Lynch
Journal:  Addiction       Date:  2008-06       Impact factor: 6.526

8.  Buprenorphine effects on cigarette smoking.

Authors:  N K Mello; S E Lukas; J H Mendelson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial.

Authors:  Caryn Lerman; Vyga Kaufmann; Margaret Rukstalis; Freda Patterson; Kenneth Perkins; Janet Audrain-McGovern; Neal Benowitz
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

10.  Contingent reinforcement for reduced carbon monoxide levels in methadone maintenance patients.

Authors:  J M Schmitz; H Rhoades; J Grabowski
Journal:  Addict Behav       Date:  1995 Mar-Apr       Impact factor: 3.913

View more
  33 in total

1.  Financial incentives for abstinence among socioeconomically disadvantaged individuals in smoking cessation treatment.

Authors:  Darla E Kendzor; Michael S Businelle; Insiya B Poonawalla; Erica L Cuate; Anshula Kesh; Debra M Rios; Ping Ma; David S Balis
Journal:  Am J Public Health       Date:  2014-11-13       Impact factor: 9.308

Review 2.  Monetary-based consequences for drug abstinence: methods of implementation and some considerations about the allocation of finances in substance abusers.

Authors:  Jesse Dallery; Bethany Raiff
Journal:  Am J Drug Alcohol Abuse       Date:  2011-12-13       Impact factor: 3.829

3.  Breath carbon monoxide output is affected by speed of emptying the lungs: implications for laboratory and smoking cessation research.

Authors:  Bethany R Raiff; Crystal Faix; Marissa Turturici; Jesse Dallery
Journal:  Nicotine Tob Res       Date:  2010-06-07       Impact factor: 4.244

4.  Early quit days among methadone-maintained smokers in a smoking cessation trial.

Authors:  Marcel A de Dios; Bradley J Anderson; Celeste M Caviness; Michael D Stein
Journal:  Nicotine Tob Res       Date:  2014-06-20       Impact factor: 4.244

Review 5.  Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.

Authors:  Sarah C Akerman; Mary F Brunette; Alan I Green; Daisy J Goodman; Heather B Blunt; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2014-12-22

Review 6.  Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.

Authors:  Mollie E Miller; Stacey C Sigmon
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

Review 7.  Contingency Management: New Directions and Remaining Challenges for An Evidence-Based Intervention.

Authors:  Carla J Rash; Maxine Stitzer; Jeremiah Weinstock
Journal:  J Subst Abuse Treat       Date:  2016-09-28

8.  Contingency management for behavior change: applications to promote brief smoking cessation among opioid-maintained patients.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Stacey C Sigmon
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

Review 9.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

10.  Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence-contingent incentives in residential substance abuse treatment patients.

Authors:  Sheila M Alessi; Nancy M Petry
Journal:  Nicotine Tob Res       Date:  2014-06-16       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.